IQM-QUANTUM-COMPUTERS
7.4.2022 17:23:05 CEST | Business Wire | Press release
IQM Quantum Computers , Hebrew University of Jerusalem and Bar-Ilan University have started a research cooperation on quantum technologies, with IQM providing commercial-grade quantum-computing hardware components to both universities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005722/en/
IQM, the Pan-European leader in quantum computers, Hebrew University of Jerusalem and Bar-Ilan University, among the leading universities in the world, announced today cooperation in quantum computing focused on research, exchange of know-how and quantum hardware.
The purpose of the cooperation is to provide the researchers at the Hebrew University of Jerusalem (in the group led by Professor Nadav Katz within its Physics Department and Quantum Information Science Center) and Bar-Ilan University (in the group led by Professor Michael Stern, of the Department of Physics) commercial-grade quantum-computing hardware developed by IQM. Researchers in these groups will conduct experiments using the IQM hardware and further advance scientific development.
The initiative also includes testing IQM’s qubit technology and conducting experiments based on its hardware. This long-term cooperation will result in significant scientific breakthroughs, several academic contributions and new product innovations. This is in line with IQM’s chosen strategy of providing its customers and partners direct access to hardware components.
Speaking about this announcement, Dr. Juha Vartiainen, COO and cofounder of IQM, said, “We are very happy to be working with both the Hebrew University of Jerusalem and Bar-Ilan University and look forward to a fruitful, long-term scientific and commercial cooperation. This announcement aligns well with our strategy to provide commercial-grade quantum-computing hardware to global research groups.”
“This cooperation is also a significant milestone for our cooperation with the world-class quantum ecosystem in Israel. As quantum computers develop further, the know-how developed in Israel—for example, around machine learning and quantum software—is going to become more critical in the future,” added Juha.
In the future, all parties also aim to extend the collaboration toward building full-stack quantum computers for scientific and commercial purposes in Israel.
“We are excited about this new collaboration with IQM and have already measured several consistently high-coherence IQM devices in our lab in Israel. This is just the beginning of a productive and fruitful joint venture,” shared Prof. Nadav Katz, director of HUJI’s Quantum Information Science Center.
Highly coherent controlled oscillations of IQM’s qubits measured in Israel (HUJI).
“We are proud to take part in a study that places Israel and its universities at the forefront of the global effort to develop quantum computers. The road is still long, but I believe that we at Bar-Ilan, together with our partners at the Hebrew University, will succeed in achieving groundbreaking results,” said Prof. Michael Stern.
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM provides on-premises quantum computers for supercomputing data centers and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer, which will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has over 160 employees with offices in Paris, Bilbao, Munich and Espoo.
For more information: www.meetiqm.com
Recent IQM announcements:
- BioNTech Chief Operating Officer Dr. Sierk Poetting is to steer IQM global expansion as chairman .
- IQM continues its European expansion; the new French subsidiary will focus on IQM’s co-design customers in aviation, space and cybersecurity.
- IQM has opened its exclusive quantum fabrication facility in Finland.
- IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
- IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.
Registered office:
IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland
About the Hebrew University of Jerusalem:
The Hebrew University of Jerusalem (HUJI) is Israel’s leading academic and research institution, serving over 25,000 students from some 80 countries on 6 campuses. Founded in 1918 by luminaries including Albert Einstein, Chaim Weizmann, Sigmund Freud and Martin Buber, HUJI is ranked in the top echelon of the world’s leading universities. To date, HU faculty and alumni have won 8 Nobel Prizes, 1 Fields Medal and 1 Abel Prize—a proud tradition of innovation and excellence.
About Bar-Ilan University:
Bar-Ilan University, founded in 1955, is one of Israel’s leading institutions of higher education, uniquely combining cutting-edge scientific research with education steeped in Jewish values and social responsibility. Having grown from 70 students to close to 20,500 students, its milestone achievements in the sciences and humanities and all fields of human endeavor have made an indelible imprint on the landscape of the State of Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom